Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04613596
Registration number
NCT04613596
Ethics application status
Date submitted
28/10/2020
Date registered
3/11/2020
Date last updated
24/04/2024
Titles & IDs
Public title
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Query!
Scientific title
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Query!
Secondary ID [1]
0
0
849-007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Non-Small Cell Lung Cancer
0
0
Query!
Metastatic Non-Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Adagrasib
Treatment: Drugs - Adagrasib
Treatment: Drugs - Adagrasib
Treatment: Drugs - Adagrasib
Treatment: Drugs - Pembrolizumab
Experimental: Phase 2 Cohort 1a: PD-L1 TPS <1% - Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab
Experimental: Phase 2 Cohort 1b: PD-L1 TPS <1% - Cohort 1b: Adagrasib BID monotherapy
Experimental: Phase 2 Cohort 2: PD-L1 TPS =1% - Cohort 2: Adagrasib BID in combination with pembrolizumab
Experimental: Phase 3 Cohort 3 Investigational Arm - Adagrasib BID in combination with pembrolizumab
Active Comparator: Phase 3 Cohort 4 Comparator Arm - Pembrolizumab
Treatment: Drugs: Adagrasib
Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)
Treatment: Drugs: Adagrasib
Adagrasib 600 mg BID monotherapy (Cohort 1b)
Treatment: Drugs: Adagrasib
adagrasib 400 mg BID in combination with pembrolizumab
Treatment: Drugs: Adagrasib
Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W
Treatment: Drugs: Pembrolizumab
Pembrolizumab 200 mg IV Q3W
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.
Query!
Assessment method [1]
0
0
Objective Response Rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Query!
Timepoint [1]
0
0
22 months
Query!
Primary outcome [2]
0
0
Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab
Query!
Assessment method [2]
0
0
Progression Free Survival per RECIST 1.1 by Blinded Independent Central Review (BICR) and Overall Survival
Query!
Timepoint [2]
0
0
36 months
Query!
Secondary outcome [1]
0
0
Phase 2: To characterize the safety and tolerability of study treatments in selected populations
Query!
Assessment method [1]
0
0
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and laboratory abnormalities.
Query!
Timepoint [1]
0
0
22 months
Query!
Secondary outcome [2]
0
0
Phase 2: Duration of Response
Query!
Assessment method [2]
0
0
Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.
Query!
Timepoint [2]
0
0
22 months
Query!
Secondary outcome [3]
0
0
Phase 2: Progression Free Survival
Query!
Assessment method [3]
0
0
Defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.
Query!
Timepoint [3]
0
0
22 months
Query!
Secondary outcome [4]
0
0
Phase 2: To evaluate secondary efficacy endpoints using the study treatment in selected populations
Query!
Assessment method [4]
0
0
1-Year Survival rate
Query!
Timepoint [4]
0
0
12 months
Query!
Secondary outcome [5]
0
0
Phase 2: To evaluate secondary efficacy endpoints using the study treatment in selected populations
Query!
Assessment method [5]
0
0
Overall Survival (OS)
Query!
Timepoint [5]
0
0
22 months
Query!
Secondary outcome [6]
0
0
Phase 2: To evaluate the pharmacokinetics (PK) of study treatments by measuring blood plasma MRTX849 and potential metabolite concentrations.
Query!
Assessment method [6]
0
0
Pharmacokinetics (PK) Blood plasma Adagrasib and potential metabolite concentrations
Query!
Timepoint [6]
0
0
22 months
Query!
Secondary outcome [7]
0
0
Phase 3: To evaluate the safety and tolerability in the study population
Query!
Assessment method [7]
0
0
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and laboratory abnormalities.
Query!
Timepoint [7]
0
0
36 months
Query!
Secondary outcome [8]
0
0
Phase 3: To evaluate the PK of adagrasib administered in the study population
Query!
Assessment method [8]
0
0
Pharmacokinetics (PK) Blood plasma Adagrasib and potential metabolite concentrations
Query!
Timepoint [8]
0
0
36 months
Query!
Secondary outcome [9]
0
0
Phase 3: To evaluate health-related quality of life (HRQOL) and lung cancer specific symptoms in the study population
Query!
Assessment method [9]
0
0
Patient Reported Outcomes to measure quality of life
Query!
Timepoint [9]
0
0
36 months
Query!
Secondary outcome [10]
0
0
Phase 3: Progression Free Survival per RECIST 1.1 by Investigator
Query!
Assessment method [10]
0
0
Defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.
Query!
Timepoint [10]
0
0
36 months
Query!
Secondary outcome [11]
0
0
Phase 3: Duration of Response (DOR) per RECIST 1.1 by Investigator and BICR
Query!
Assessment method [11]
0
0
Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.
Query!
Timepoint [11]
0
0
36 months
Query!
Secondary outcome [12]
0
0
Phase 3: Objective Response Rate (ORR) per RECIST 1.1 by Investigator and BICR
Query!
Assessment method [12]
0
0
Defined as the percent of patients documented to have a confirmed CR or PR.
Query!
Timepoint [12]
0
0
36 months
Query!
Eligibility
Key inclusion criteria
- Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with
KRAS G12C mutation and any PD-L1 TPS
- Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or
nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50%
- Phase 3: Presence of evaluable or measurable disease per RECIST
- Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of
the following:
1. No evidence of brain metastases
2. Untreated brain metastases not needing immediate local therapy
3. Previously treated brain metastases not needing immediate local therapy
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC
including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting
KRAS G12C mutation (e.g., AMG 510).
- Phase 2: Active brain metastases
- Phase 3: Patients with known central nervous system (CNS) lesions must not have any of
the following:
1. Any untreated brain lesions > 1.0 cm in size
2. Any brainstem lesions
3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions
at a total daily dose of > 10 mg of prednisone (or equivalent) prior to
randomization.
4. Have poorly controlled (> 1/week) generalized or complex partial seizures, or
manifest neurologic progression due to brain lesions notwithstanding CNS-directed
therapy
- Phase 3: Radiation to the lung > 30 Gy within 6 months prior to the first dose of
study treatment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2/Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
2/12/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/10/2029
Query!
Actual
Query!
Sample size
Target
806
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Wollongong
Query!
Recruitment hospital [2]
0
0
Research Site - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Research Site - Bedford Park
Query!
Recruitment hospital [4]
0
0
Research Site - Ballarat
Query!
Recruitment postcode(s) [1]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [4]
0
0
3350 - Ballarat
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Mississippi
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nevada
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Jersey
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Ohio
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oregon
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Dakota
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Virginia
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Carinthia
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Linz
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Vienna
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Antwerpen
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Vlaams Brabant
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Hasselt
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Alberta
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
British Columbia
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Ontario
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Central Bohemian
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Olomouc
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Ostrava
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Praha
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Baden-Wuerttemberg
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Bavaria
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Bayern
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Hessen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Schleswig-Holstein
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Frankfurt
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Gießen
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Hemer
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Oldenburg
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Budapest
Query!
Country [51]
0
0
Hungary
Query!
State/province [51]
0
0
Gyöngyös
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Torokbalint
Query!
Country [53]
0
0
Ireland
Query!
State/province [53]
0
0
Dublin
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Afula
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Be'er Sheva
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Haifa
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Jerusalem
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Re?ovot
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Safed
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Forli-Cesena
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Bari
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Bologna
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Genova
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Milan
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Napoli
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Parma
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Roma
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Rome
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Varese
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Gyeonggi-do
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Busan
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Cheongju-si
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Daegu
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Goyang-si
Query!
Country [75]
0
0
Korea, Republic of
Query!
State/province [75]
0
0
Seoul
Query!
Country [76]
0
0
Netherlands
Query!
State/province [76]
0
0
Noord-Holland
Query!
Country [77]
0
0
Netherlands
Query!
State/province [77]
0
0
Zuid-Holland
Query!
Country [78]
0
0
Netherlands
Query!
State/province [78]
0
0
Harderwijk
Query!
Country [79]
0
0
Netherlands
Query!
State/province [79]
0
0
Utrecht
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Gdansk
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Lublin
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Otwock
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Skorzewo
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Torun
Query!
Country [85]
0
0
Portugal
Query!
State/province [85]
0
0
Lisbon
Query!
Country [86]
0
0
Portugal
Query!
State/province [86]
0
0
Porto
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Barcelona
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
La Coruña
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Madrid
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Málaga
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Santiago De Compostela
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Sevilla
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Valencia
Query!
Country [94]
0
0
Taiwan
Query!
State/province [94]
0
0
Tainan City
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
England
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Leicester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Mirati Therapeutics Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy
and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS
G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
The Phase 3 portion of the study compares the efficacy of adagrasib in combination with
pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or
metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50% and who are
candidates for first line treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04613596
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Barbara Wamil, MD
Query!
Address
0
0
Mirati Therapeutics Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Mirati Therapeutics Study Locator Services
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
18448935530
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04613596
Download to PDF